Marja-Liisa Lokki

Dr. Marja-Liisa Lokki


Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 December 2006 in Tissue Antigens
Verified
Journal Article
Closed access
PDF file
APA. Palikhe
A. Palikhe
JSJ. Sinisalo
J. Sinisalo
MSM. Seppänen
M. Seppänen
VVV. Valtonen
V. Valtonen
MNM. S. Nieminen
M. S. Nieminen
MLMarja-Liisa Lokki
Marja-Liisa Lokki

22 November 2018 in HLA
Verified
Journal Article
Closed access
PDF file
MLMarja-Liisa Lokki
Marja-Liisa Lokki
RPRiitta Paakkanen
Riitta Paakkanen

6 December 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
MSMohammadreza Shoghli
Mohammadreza Shoghli
A. Inkeri LokkiA. Inkeri Lokki
A. Inkeri Lokki
MLMitja Lääperi
Mitja Lääperi
JSJuha Sinisalo
Juha Sinisalo
MLMarja-Liisa Lokki
Marja-Liisa Lokki
RLReijo Laaksonen
Reijo Laaksonen
Ceramides and other sphingolipids are implicated in vascular dysfunction and inflammation. They have been suggested as potential biomarkers for hypertension. However, their specific association with hypertension prevalence and onset requires further investigation. This study aimed to identify specific ceramide and phosphatidylcholine species associated with hypertension prevalence and onset. The 2002 FINRISK (Finnish non-communicable risk factor survey) study investigated the association between coronary event risk scores (CERT1 and CERT2) and hypertension using prevalent and new-onset hypertension groups, both consisting of 7722 participants, over a span of 10 years. Ceramide and phosphatidylcholine levels were measured using tandem liquid chromatography-mass spectrometry. Ceramide and phosphatidylcholine ratios, including ceramide (d18:1/18:0), ceramide (d18:1/24:1), phosphatidylcholine (16:0/16:0), and the ratio of ceramide (d18:1/18:0)/(d18:1/16:0), are consistently associated with both prevalence and new-onset hypertension. Ceramide (d18:1/24:0) was also linked to both hypertension measures. Adjusting for covariates, CERT1 and CERT2 showed no-longer-significant associations with hypertension prevalence, but only CERT2 predicted new-onset hypertension. Plasma ceramides and phosphatidylcholines are crucial biomarkers for hypertension, with imbalances potentially contributing to its development. Further research is needed to understand the underlying mechanisms by which ceramides will contribute to the development of hypertension.

1 March 2003 in Clinical and Vaccine Immunology
Verified
Journal Article
Closed access
TJTaina Jaatinen
Taina Jaatinen
MLMeri Lahti
Meri Lahti
OROlli Ruuskanen
Olli Ruuskanen
RKRiikka Kinos
Riikka Kinos
LTLennart Truedsson
Lennart Truedsson
MLMarja-Liisa Lokki
Marja-Liisa Lokki
Deficiencies of the early components of the classical complement pathway impair the actions of innate and humoral immunity and may lead to increased susceptibility to infections. We have studied the genetic basis of total C4B deficiency in a Finnish patient with recurrent meningitis, chronic fistulas and abscesses. The maternal chromosome carried a four-gene deletion including the C4B gene, and a conversion from C4B to C4A gene was found on the paternal chromosome resulting in complete deficiency of C4B. In the converted C4A gene, mutation screening did not reveal any amino acid changes or prominent mutations, yet a large number of nucleotide variations were found. Further, the patient was heterozygous for structural deficiency of mannan binding lectin (MBL) associating with medium levels of serum MBL. Our data provides new information on the genetic instability of the C4 gene region, and on the association of homozygous C4B deficiency and variant MBL genotype with increased susceptibility to recurrent and chronic infections. Importantly, plasma therapy induced a prompt clinical cure with long-term effects.

30 June 2010 in Atherosclerosis Supplements
Verified
Journal Article
Closed access
MGM. Granér
M. Granér
ORO. Rimpiläinen
O. Rimpiläinen
HTH. Tikkanen
H. Tikkanen
MLMarja-Liisa Lokki
Marja-Liisa Lokki
MNM.S. Nieminen
M.S. Nieminen
JSJ. Sinisalo
J. Sinisalo

1 January 2005
Verified
Journal Article
Closed access
MLMarja-Liisa Lokki
Marja-Liisa Lokki